Human papillomavirus type 59 L1 capsid protein (HPV 59 L1)

The Human papillomavirus type 59 (HPV 59) L1 capsid protein is the primary structural component of the viral shell, playing a critical role in the viral life cycle. As the major capsid protein, L1 mediates the initial attachment of the virus to the host cell's basement membrane and subsequent entry into basal epithelial cells (UniProt P36732). HPV 59 is classified as a high-risk (HR) genotype, significantly associated with the development of cervical intraepithelial neoplasia and invasive cervical cancer (IARC Monograph Vol 100B). The L1 protein has the unique ability to self-assemble into non-infectious virus-like particles (VLPs), which retain the native antigenic structure of the virus. These VLPs serve as the basis for prophylactic vaccines, designed to elicit high titers of neutralizing antibodies that block viral infection. While not included in current widely available 9-valent vaccines, HPV 59 L1 is a key target for next-generation multivalent vaccine candidates, such as 14-valent formulations (SCT510), aiming to provide broader protection against oncogenic HPV types (PubMed PMID: 33130550). Monitoring the expression and sequence variation of the L1 protein is essential for evaluating vaccine efficacy and potential viral escape in different populations.

Other names

Major capsid protein L1HPV59 L1L1 protein of HPV 59L1 capsid protein

Prophylactic immunization via the induction of neutralizing antibodies that prevent viral entry into host basal epithelial cells.